Mirum Pharmaceuticals, Inc.

MIRM·NasdaqGM·Healthcare
Compare
86.06+0.05 (+0.06%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD
After hours86.060.00 (0.00%)Oct 12, 4:27 PM EDT

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close86.01
Open86.95
Day range81.9588.30
52-week range63.23130.00
Off day high−2.54%
Off 52-week high−33.80%
Volume1.21M
Avg. volume (3M)705.14K
Market cap5.59B
EPS (TTM)-14.10
Forward P/E-248.25
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)0.62
Shares outstanding64.93M
Short interest13.85% of float
Earnings dateAug 5, 2026
Analyst target146.29
Profit margin−139.18%

Against its peers

Compare in full ›
MIRM IONS TVTX BMRN ARWR RARE
Market cap 5.59B 7.26B 4.90B 10.72B 8.58B 1.51B
P/E (TTM) — — — 149.7 — —
Forward P/E -248.2 -39.3 9.2 8.3 -12.3 25.8
Price/book -534.5 16.4 200.1 1.7 18.4 -5.2
Dividend yield — — — — — —
1-year change +19.18% −35.85% +98.95% +4.48% +68.88% −51.66%
Today +0.06% −3.56% −0.20% +1.09% −3.22% −1.16%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All MIRM news ›
Seeking Alpha·Positive

Mirum Pharmaceuticals to report Livmarli trial results Monday

(MIRM:NASDAQ) Seeking Alpha Grandbrothers/iStock Editorial via Getty Images Mirum Pharmaceuticals (MIRM) said it will release topline results from a late-stage clinical trial of its Livmarli treatment on Monday, October 12, providing…

Grafa·

Mirum reports LIVMARLI Phase 3 trial success

Assets related to this article Mirum Pharmaceuticals (NASDAQ:MIRM) announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) in patients aged 6 months and older with ultra-rare cholestatic liver diseases,…

From articles in the 4Search news index.

In the news

16mentions in 30 days
11with it in the headline
Positivesentiment

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 16 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.